Vertex Pharmaceuticals Stock Filter Stocks by Fundamentals
| VRTX Stock | USD 393.48 0.38 0.1% |
Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
Vertex | Shares Owned by Institutions |
Vertex Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.Environment Score | Governance Score | Social Score |
Vertex Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Vertex Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vertex Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vertex Pharmaceuticals' value.| Shares | Massachusetts Financial Services Company | 2023-12-31 | 3.6 M | Capital Research Global Investors | 2023-12-31 | 3.6 M | Loomis, Sayles & Company Lp | 2023-12-31 | 3.1 M | Norges Bank | 2023-12-31 | 3 M | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 3 M | Goldman Sachs Group Inc | 2023-12-31 | 3 M | Amundi | 2023-12-31 | 2.7 M | Northern Trust Corp | 2023-12-31 | 2.7 M | Ubs Asset Mgmt Americas Inc | 2023-12-31 | 2.6 M | Vanguard Group Inc | 2023-12-31 | 22.3 M | Blackrock Inc | 2023-12-31 | 21.9 M |
Vertex Fundamentals
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 91.41 B | ||||
| Shares Outstanding | 258.46 M | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 97.34 % | ||||
| Number Of Shares Shorted | 3.98 M | ||||
| Price To Earning | 24.57 X | ||||
| Price To Book | 5.83 X | ||||
| Price To Sales | 10.38 X | ||||
| Revenue | 9.84 B | ||||
| Gross Profit | 5.32 B | ||||
| EBITDA | 3.93 B | ||||
| Net Income | 3.62 B | ||||
| Cash And Equivalents | 9.77 B | ||||
| Cash Per Share | 38.06 X | ||||
| Total Debt | 808.4 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.70 X | ||||
| Book Value Per Share | 68.22 X | ||||
| Cash Flow From Operations | 3.54 B | ||||
| Short Ratio | 3.84 X | ||||
| Earnings Per Share | 13.87 X | ||||
| Price To Earnings To Growth | 0.53 X | ||||
| Target Price | 465.18 | ||||
| Number Of Employees | 5.4 K | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 101.88 B | ||||
| Total Asset | 22.73 B | ||||
| Retained Earnings | 10.14 B | ||||
| Working Capital | 10.6 B | ||||
| Current Asset | 1.41 B | ||||
| Current Liabilities | 506.35 M | ||||
| Net Asset | 22.73 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vertex Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vertex Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vertex Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vertex Pharmaceuticals Stock:Check out Vertex Pharmaceuticals Piotroski F Score and Vertex Pharmaceuticals Altman Z Score analysis. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.87 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.